Technical Analysis for STRO - Sutro Biopharma, Inc.

Grade Last Price % Change Price Change
grade F 10.03 -2.81% -0.29
STRO closed down 2.81 percent on Wednesday, February 20, 2019, on 22 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical STRO trend table...

Date Alert Name Type % Chg
Feb 20 20 DMA Resistance Bearish 0.00%
Feb 20 Fell Below 50 DMA Bearish 0.00%
Feb 20 180 Bearish Setup Bearish Swing Setup 0.00%
Feb 20 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Feb 20 Stochastic Buy Signal Bullish 0.00%
Feb 20 Earnings Movers Other 0.00%
Feb 20 Oversold Stochastic Weakness 0.00%
Feb 19 Crossed Above 50 DMA Bullish -2.81%
Feb 19 Multiple of Ten Bullish Other -2.81%
Feb 19 Oversold Stochastic Weakness -2.81%

Older signals for STRO ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Medicine Cancer Clinical Medicine Alpha Immunology California Antibodies Drug Discovery Cancer Treatments Antineoplastic Drugs Multiple Myeloma Sutro Biopharma Autoimmune Disorders Non Hodgkin Lymphoma Adc Immunogen South San Francisco Therapeutics For Cancer Milatuzumab
Is STRO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.9
52 Week Low 8.5
Average Volume 41,815
200-Day Moving Average 0.0
50-Day Moving Average 10.2757
20-Day Moving Average 10.4708
10-Day Moving Average 10.389
Average True Range 0.8541
ADX 21.5
+DI 17.494
-DI 11.4569
Chandelier Exit (Long, 3 ATRs ) 9.3877
Chandelier Exit (Short, 3 ATRs ) 12.2523
Upper Bollinger Band 11.1529
Lower Bollinger Band 9.7887
Percent B (%b) 0.18
BandWidth 13.028613
MACD Line -0.0805
MACD Signal Line -0.0111
MACD Histogram -0.0694
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.78
Resistance 3 (R3) 10.85 10.68 10.66
Resistance 2 (R2) 10.68 10.49 10.64 10.61
Resistance 1 (R1) 10.35 10.37 10.27 10.28 10.57
Pivot Point 10.18 10.18 10.13 10.14 10.18
Support 1 (S1) 9.85 9.99 9.77 9.78 9.49
Support 2 (S2) 9.68 9.87 9.64 9.45
Support 3 (S3) 9.35 9.68 9.41
Support 4 (S4) 9.28